Ventyx Biosciences, Inc. (VTYX) NASDAQ
14.00
+0(+0.00%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
14.00
+0(+0.00%)
Currency In USD
| Previous Close | 14 |
| Open | 14 |
| Day High | 14 |
| Day Low | 14 |
| 52-Week High | 25 |
| 52-Week Low | 0.78 |
| Volume | 5.4M |
| Average Volume | 3.81M |
| Market Cap | 1B |
| PE | -9.4 |
| EPS | -1.49 |
| Moving Average 50 Days | 12.84 |
| Moving Average 200 Days | 6.4 |
| Change | 0 |
Data not available
Ventyx Provides Clinical and Corporate Updates
GlobeNewswire Inc.
Dec 02, 2025 12:02 PM GMT
Strengthening our Advisory Board with addition of Mark McKenna as Strategic Advisor and Peter Libby, MD as a Clinical AdvisorExpanding the Phase 2 recurrent pericarditis study into Canada, EU and the UK to evaluate QD dose ranging in preparation for
Ventyx Biosciences to Participate in the Piper Sandler 37th Annual Healthcare Conference
GlobeNewswire Inc.
Dec 01, 2025 12:02 PM GMT
SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammation-mediated cardiovas
Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference in London
GlobeNewswire Inc.
Nov 17, 2025 12:02 PM GMT
SAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammation-mediated cardiovas